What the business is
Braxia runs ketamine clinics and clinical trials for depression; KetaMD is an at-home ketamine telemedicine platform
The bet
That buying KetaMD would give Braxia the technology, logistics and know-how to deliver supervised at-home ketamine treatment across the US and Canada
Starting capital
Company-valued maximum of $6.3M: 42 million Braxia shares worth about $2M at the $0.049 close, plus around $1M more in five-year earnout shares
How it started
KetaMD built a telemedicine platform for at-home ketamine treatment for anxiety and depression, medically supervised, guided by mental-health nurses and backed by psychiatrists, available only in Florida. Braxia Scientific, a Toronto-based company working on depression, suicidality and related conditions, ran clinics and trials and had watched ketamine outcomes firsthand.
What happened
On 3 August 2022 Braxia announced the share purchase: 100% of KetaMD's common stock for 42 million Braxia shares — about $2 million at the $0.049 close — plus roughly $1 million in earnout shares tied to five-year performance targets, a maximum total the company put at $6.3 million. KetaMD would keep its brand under Braxia.
What has to be true
Clinics scale city by city; telehealth was the only way to reach patients across the US without building clinics.
Braxia had seen ketamine outcomes in its own clinics and trials and wanted a direct-to-patient channel while the field was young.
An all-stock deal at a penny-stock price let a small company buy a working platform without spending cash.
KetaMD gained a parent with clinical credibility; Braxia gained a live Florida market and a five-state rollout plan.
What can be applied
A treatment business that scales room by room buys national reach by acquiring the telehealth rails instead of building clinics city by city.
Aftermath
As of 3 August 2022 the KetaMD brand was set to remain standalone under Braxia, with launches planned that year in California, New York, Texas, Colorado and Washington. CEO Roger McIntyre framed the deal as accelerating access to evidence-based psychedelics across the US and Canada, and globally in the future. The report carried no post-acquisition results.
FOLLOW THE EVIDENCE